Journal of Clinical Diabetes
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Mini Review   
  • J Clin Diabetes 2022, Vol 6(4): 147
  • DOI: 10.4172/jcds.1000147

The Effect of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors on Urinary Tract Infections

Ethan M Fan1, Zheyar J Seyan2, Jacob B Hogins2, Alana L Christie3, Marconi Abreu4, Larry J Reitzer2 and Philippe E Zimmern1*
1Department of Urology, University of Texas Southwestern Medical Center 5323 Harry Hines Blvd Dallas, TX 75390-9110, U.S.A
2Department of Biological Sciences, The University of Texas at Dallas 800 W. Campbel RoadRichardson, TX 75080, U.S.A
3Simmons Comprehensive Cancer Center Biostatistics, University of Texas SouthwesternMedical Center 6000 Harry Hines Blvd Dallas, TX 75390-8852, U.S.A
4Division of Endocrinology, University of Texas Southwestern Medical Center, 2001 Inwood Rd, 8th Floor Dallas, TX 75390, U.S.A
*Corresponding Author : Philippe E Zimmern, Department of Urology, University of Texas Southwestern Medical Center 5323 Harry Hines Blvd Dallas, TX 75390-9110, U.S.A, Email: Philippe.Zimmrn@UTSouthwestern.edu

Received Date: Jun 29, 2022 / Published Date: Jul 29, 2022

Abstract

Objective: Sodium-glucose cotransporter-2 inhibitors are used to treat diabetes by increasing glucose excretion into urine, leading to glycosuria. Although glycosuria increases risk of urinary tract infections, there is a lack of strong evidence showing such an increase with sodium-glucose cotransporter-2 inhibitor use.

Methods: Urine samples from Sodium-glucose cotransporter-2 inhibitor-exposed diabetic patients were inoculated with strains of E. coli (UTI89, LRPF007, and W3110), and bacterial growth was measured using changes in OD600.

Results: Change in OD600 was significantly higher for the nonpathogenic W3110 strain in diabetic patients with history of recurrent urinary tract infections compared to those with no or sporadic history of urinary tract infections. Conclusion: The two uropathogenic strains grew well in urine from all patient groups, possibly due to having defenses against the inhibitory factors in urine that prevent bacterial growth. Sodium-glucose cotransporter-2 inhibitor-exposed patients do not have more Urinary tract infections than the general population because they may have sufficient levels of inhibitory factors to prevent infection.

Citation: Fan EM, Seyan ZJ, Hogins JB, Christie AL, Abreu M, et al. (2022) The Effect of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors on Urinary Tract Infections. J Clin Diabetes 6: 147. Doi: 10.4172/jcds.1000147

Copyright: © 2022 Fan EM, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Top